AGM
SRPT icon

Alpine Global Management’s Sarepta Therapeutics SRPT Stock Holding History

Alpine Global Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.1K Buy
3,570
+500
+16% +$9.68K ﹤0.01% 213
2025
Q4 		$46K Buy
3,070
+70
+2% +$1.48K 0.01% 306
2025
Q3 		$3K Buy
+3,000
New +$53.5K ﹤0.01% 207

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpine Global Management's SRPT Position: Q4 2014 in Review

Alpine Global Management sold out of Sarepta Therapeutics (SRPT) in Q4 2014, closing a stake of 15,000 shares — an estimated $317K sold.

Alpine Global Management first reported a position in SRPT in Q1 2014 and held it in 3 quarters. The position peaked at $745K in Q2 2014. 120 funds tracked by Wall St. Rank hold SRPT as of Q4 2014.

  • Alpine Global Management reported no remaining Sarepta Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Alpine Global Management sold 15,000 Sarepta Therapeutics shares in Q4 2014, an estimated $317K.
  • Alpine Global Management first reported a position in Sarepta Therapeutics in Q1 2014 and held it in 3 quarters.
  • Alpine Global Management's Sarepta Therapeutics position peaked at $745K in Q2 2014.
  • 120 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2014.

Based on Alpine Global Management's 13F filing for Q4 2014, filed 12 Feb 2015.